Develops T cell therapies for cancer and autoimmune diseases.
Jun 2026Revenue $117M/yrExpenses $365M/yr
No trendCash runway ≈ 10 months from Jun 2026
Figures by year
When will Autolus Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $117M and expenses $365M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $75.4M | $346M | −$271M |
| Dec 2024 | $10.1M | $252M | −$241M |
| Dec 2023 | $1.70M | $181M | −$180M |
| Dec 2019 | $2.91M | $149M | −$146M |
| Sep 2018 | $1.41M | $58.9M | −$57.5M |
| Sep 2017 | $1.69M | $25.1M | −$23.4M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.